Photo taken from Elisabetta Bonzano/X
Sep 17, 2024, 10:36
Elisabetta Bonzano: First-line carboplatin-cyclophosphamid versus paclitaxel for mTNBC
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:
“ First-line carboplatin–cyclophosphamid (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC):
Results from a multicenter, randomized phase lIb trial: The Triple-B study (BOOG 2013-01).
By Marleen Kok Lab.”
Source: Elisabetta Bonzano/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14